Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose adolescent Bexsero booster after infant MenB immunization
2017-004732-11Phase 4Completed
- Sponsor
- University of Oxford
- Start
- Dec 2017
- Countries
- 1
01
Overview
Phase 4 trial of meningococcal group B vaccine in meningococcal disease (2 arms), sponsored by University of Oxford. Primary endpoint: Serum bactericidal activity against group B meningococcal strains before and after immunisation. Started Dec 2017; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2017-004732-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004732-11.